France (FR)

Diamond formation kinetics in shock-compressed C─H─O samples recorded by small-angle x-ray scattering and x-ray diffraction (2022) He Z, Rödel M, Lütgert J, Bergermann A, Bethkenhagen M, Chekrygina D, Cowan TE, et al. Journal article Considering land cover and land use (LCLU) in lumped parameter modeling in forest dominated karst catchments (2022) Sivelle V, Jourde H, Bittner D, Richieri B, Labat D, Hartmann A, Chiogna G Journal article Exploring the Use of ICT in Job Crafting (2022) Handke L, De Boeck G, Parker SK, Kauffeld S Conference contribution, Conference Contribution Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001)) (2022) Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, et al. Journal article, Erratum Unique characteristics of AQP4-specific T cells in patients with AQP4+neuromyelitis optica spectrum disorder (NMOSD) (2022) Saggau C, Bacher P, Esser D, Leypoldt F, Wandinger KP, Paul F, Martin R, et al. Conference contribution Non-apoptotic FAS signaling controls CD40-dependent mTOR activation and balances extrafollicular versus germinal center fate in human B cells (2022) Staniek J, Kalina T, Andrieux G, Boerries M, Janowska I, Bakardjieva M, Lorenzetti R, et al. Conference contribution The role of Butyrophilin 2a2 (Btn2a2) in T cell maturation (2022) Frech M, Uchil P, Azizov V, Schober K, Irla M, Sarter K, Zaiss M Conference contribution A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information (2022) Gräf M, Knitza J, Leipe J, Krusche M, Welcker M, Kuhn S, Mucke J, et al. Conference contribution A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution